Lilly to acquire Calytrix Bio for up to $1.5 billion

Eli Lilly has agreed to acquire Calytrix Bio in a deal worth up to $1.5 billion in cash, expanding Lilly’s presence in rare blood cancers.

Calytrix’s lead program is a preclinical biparatopic antibody targeting mutant calreticulin (mCALR), for essential thrombocythemia and myelofibrosis.

The total includes an undisclosed upfront payment and additional payments tied to clinical and regulatory milestones. The companies have not disclosed the upfront amount or expected closing date.

Founded in 2025 by J.P. Morgan Life Sciences Private Capital, Calytrix also received backing from Westlake BioPartners and Avoro Ventures.

The candidate remains preclinical, so it has not yet been shown to be safe or effective in people. The deal is a pipeline bet, not an approval or near-term treatment launch.

Sources:

Calytrix Bio enters an agreement to be acquired by Lilly to advance outcomes for patients living with essential thrombocythemia and myelofibrosis

Lilly secures another myelofibrosis option via $1.5B deal for JPM-founded Calytrix

Lilly adds to buyout streak with $1.5B purchase of startup Calytrix

Eli Lilly to Buy Calytrix Bio for Up to $1.5 Billion

Lilly to buy Calytrix Bio for up to $1.5 billion

Lilly to buy Calytrix Bio for up to $1.5 billion

Eli Lilly Makes $1.5 Billion Move Beyond Weight-Loss Drugs

Lilly expands myeloproliferative neoplasm presence with up to $1.5B Calytrix buy

Lilly’s early-stage M&A quest finds $1.5B deal for Calytrix’s blood cancer work

Eli Lilly to acquire Calytrix Bio in deal worth up to $1.5 billion

Lilly Bets Up to $1.5 Billion on Calytrix's Preclinical Antibody

Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion

Lilly strikes again, buying Calytrix in $1.5bn deal

Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion

Lilly to acquire Calytrix Bio for up to USD 1.5 billion in ...